239 results about "Umbilical cord tissue" patented technology

Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.

Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.

Compositions and methods of using cells derived from umbilical cord tissue to stimulate and support lung tissue angiogenesis, to improve blood flow to lung tissue, to regenerate, repair, and improve lung tissue damaged by lung disease, disorder and/or injury, and to protect lung tissue from damage caused by lung disease, disorder and/or injury in a patient.

Disclosed are compositions and methods of generating and expanding tissue-progenitor cells or mature tissue cells in culture, comprising culturing intact bone marrow or intact umbilical cord tissue in a cell differentiation medium whereby tissue-progenitor cells or mature tissue cells are generated from mesenchymal stem cells and various progenitor cells present in the intact bone marrow or intact umbilical cord tissue and expanded, and methods of using the tissue-progenitor cells or mature tissue cells in processes of tissue repair or regeneration.

This invention encompasses methods, pharmaceutical compositions, and kits for modulating (e.g. reducing) the production of pro-inflammatory mediators involved in the pathology of a lung disease, disorder, and/or injury in a patient having the lung disease, disorder, and/or injury. The invention also encompasses methods, pharmaceutical compositions, and kits for inhibiting the production of pro-inflammatory mediators involved in the pathology of a lung disease, disorder, and/or injury in a patient having the lung disease, disorder, and/or injury. In one embodiment, the umbilical cord tissue-derived cells are isolated from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, lack the production of CD117 or CD45, and do not express hTERT or telomerase.

The invention relates to a separation method and a culture method for umbilical cord mesenchymal stem cells. The separation method comprises the following steps: thoroughly cleaning umbilical cord tissue of a healthy newborn by using a PBS (phosphate buffer solution) containing streptomycin and penicillin, and removing blood; shearing the umbilical cord into small sections uniform in length, and mechanically separating, bluntly stripping Wharton' s jelly, and removing umbilical arteries and umbilical veins; uniformly shearing the Wharton' s jelly; re-suspending the sheared Wharton' s jelly through an MSCs (mesenchymal stem cells) culture medium, inoculating to a culture dish with laid gelatin, and putting in a CO2 culture box for cultivation; conducting centrifugal separation to obtain tissue blocks and a cell resuspension solution. The culture method comprises the following steps: enwrapping the culture dish, discarding the gelatin, and washing with the PBS; inoculating the separated out tissue blocks and the cell resuspension into the culture dish; performing digestive subculture after cell fusion growth rate reaches 80-90%.

The invention discloses a construction method of an umbilical cord mesenchyma stem cell bank utilizing newborn umbilical cords as resources, aiming at causing the steps to be less and the operation to be simpler and easier when constructing the umbilical cord mesenchyma stem cell bank. The invention comprises the following steps: (1), taking a human umbilical cord for detection, using a buffer solution to wash and remove residual blood, shearing to pieces, thus obtaining human umbilical cord tissue; (2), adding collagenase for digestion; (3), adding the buffer solution for diluting the digested tissue followed by organizing, mixing evenly and centrifuging; (4), abandoning the supernatant, adding the buffer solution for heavy suspension precipitation, screening, collecting filtrate and centrifuging, and repeating twice to obtain the human umbilical cord mesenchyma stem cell; (5), saving the obtained human umbilical cord mesenchyma stem cell in liquid nitrogen according to ABO/Rh parting and HLA parting thereof, establishing a cell information archive for retrieval, thus constructing the human umbilical cord mesenchyma stem cell bank. Compared with the existing method, the invention is more fast and convenient, and has less damage to the cell.

The invention provides a method for storing mesenchymal stem cells and a method for culturing mesenchymal stem cells. The storing method comprises the following steps of: cutting the umbilical cord into blocks, and putting the blocks into a mixed solution of freezing storage solution and base solution in a volume rate of 1:3 for pretreatment; putting the blocks in the mixed solution of the freezing storage solution and the base solution in a volume rate of 1:1 for treatment at the temperature of 0 DEG C; putting the blocks in the freezing storage solution for treatment at the temperature of 0DEG C; and freeze-storing the blocks in liquid nitrogen. The culturing method is that the stored umbilical cord blocks are used for culture. After babies are delivered, the expensive cell culturing operation of the umbilical cords is not required immediately, the umbilical cords can be directly frozen at the deep low temperature, and the cell activity is not affected. One freezing storage tube can be picked up at any time, the umbilical cords are recovered and successfully cultured and amplified to obtain MSCs, so that the culture operation is not required to be made for each portion of umbilical cord, and the operating cost of the umbilical cord MSCs storage warehouse is greatly lowered.

The invention belongs to the technical field of biology, and discloses a method for preparing mesenchymal stem cells. The method takes a neonatal umbilical cord as a raw material and comprises the following steps: pretreating the umbilical cord; cryopreserving tissues; resuscitating the tissues; separating primary mesenchymal stem cells; and amplifying the mesenchymal stem cells. The method disclosed by the invention has the advantages being easy for industrialization and operation and the like, and can be used for cryopreserving a large quantity of umbilical cord tissues and resuscitating the umbilical cord tissues for clinical need to prepare the mesenchymal stem cells. Compared with an existing method for directly separating the mesenchymal stem cells and cryopreserving the mesenchymal stem cells, the method disclosed by the invention can be used for sufficiently preserving the most original mesenchymal stem cells contained in the umbilical cord tissues, thereby greatly reducing the preservation cost and preventing the mesenchymal stem cells from influencing clinical application after being differentiated due to multiple-time passage in vitro.

Methods for treating chronic pain, neuropathic pain or spasticity are provided. Some embodiments are to methods for treatment comprising administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. In some embodiments, administering the cells promotes repair and regeneration of nerves in the patient to decrease chronic pain, neuropathic pain or spasticity. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.

This invention relates to methods of treating stroke by intranasal administration of umbilical cord tissue-derived cells, which are isolated from mammalian umbilical cord tissue substantially free of blood or expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, and do not produce CD117 and/or telomerase. The methods of the invention regenerate, repair and improve neural tissue and improve behavior and neurological function in stroke patients.

The invention discloses application of a mesenchymal stem cell culture from a human umbilical cord or a supernatant of the mesenchymal stem cell culture. The invention provides the application of themesenchymal stem cell culture from the human umbilical cord or the supernatant of the mesenchymal stem cell culture in preparing drugs for promoting skin injury repair, promoting vascular growth, diminishing inflammation and promoting collagen fiber accumulation. The mesenchymal stem cells are derived from umbilical cord tissues and do not need to be cultured under hypoxia and other conditions, and only normal cell culture and regulation are needed; the passage number of cells is relatively-low and the cells are P3 and P4 generation cells which do not affect the dryness of the mesenchymal stemcells. Therefore, mesenchymal stem cell culture supernatant components disclosed by the application are closer to natural growth metabolic components of MSC, purer and better in treatment effect.

Methods for treating Alzheimer's disease, or the symptoms of Alzheimer's disease, are provided. Some embodiments are to methods for treatment comprising administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells, such as cell derivatives. Some embodiments are to methods for treatment comprising hUTC. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.

The invention discloses a beautifying and nursing essence and a preparation method thereof. The essence is prepared from an epidermis cell nutrient solution and contains a plurality of cell growth factors, amino acids and vitamins. The essence mainly comprises an epidermal growth factor, a fibroblast growth factor, collagen type I, a stem cell growth factor, a horn cell growth factor and amino acids and vitamins including gamma-aminobutyric acid, coenzyme Q, medical vitamin C, medical vitamin B5 and medical vitamin E. The preparation method for the essence comprises the following steps: acquisition of epidermis of umbilical cord tissue of a newborn; cell culture; collection of a cell nutrient solution; filtration sterilization; condensation of a volume; addition of active components; addition of glycerin and hyaluronic acid; etc. The beautifying and nursing essence provides a plurality of endogenous nutritional ingredients with physiological activity for the skin, can promote metabolism of epidermis cells and repair damaged cells, has a moisture retention effect and is applicable to skin beautifying and nursing.

The invention provides a preserving fluid and a preparation method therefor. The preserving fluid is used for preserving umbilical cords and/or placentas. The preserving fluid comprises 50-60g/L of dextran, 6-7g/L of sodium chloride, 200-250mg/L of calcium chloride, 200-400mg/L of potassium chloride, 1-1.2g/L of glucose and 10-30g/L of human serum albumin. The invention further discloses a preparation method for the preserving fluid. Compared with a conventional preserving fluid, the preserving fluid disclosed by the invention reduces the metabolism amount of umbilical cord tissue cells in a process of preserving the umbilical cords, and also can provide certain basic nutrient substances and energy substances to keep a low metabolism level, so that the cell activity is in a stable state, and the conditions such as shape variation or differentiation due to growth and cultivation are avoided; and moreover, the dextran in the components has an anticoagulation effect and can prevent the blood agglutination, so that the interference on the follow-up separation operation is avoided.

Provided herein are methods and kits for the isolation, processing and cryopreservation of mesenchymal cells from the Wharton's Jelly and vascular progenitor cells from umbilical cord tissue. Also provided are isolated mesenchymal cells or vascular progenitor cells obtained by the invention methods, and compositions thereof.

The invention provides a method for preparing a mesenchymal stem cell exosome. The method comprises the steps that human umbilical cord tissue surface blood is cleaned to remove epidermal and vasculartissues, Wharton jelly is taken out for cleaning, then the tissues are cut into pieces, and inoculation is performed for culture; subculturing is performed; second generation of umbilical mesenchymalstem cells are inoculated and cultured; a cell stimulator factor for promoting secretion of the exosome is added; when the cells grow to the fusion degrees 90%, first cell supernate is sucked out forseparating the exosome; the first cell supernate is centrifuged to remove cell debris, and second cell supernate is collected; the first time of ultrafiltration and concentration is conducted on thesecond cell supernate, excessive moisture is removed, and a first concentrated solution is obtained; the first concentrated solution is subjected to the second time of ultrafiltration and concentration, excessive moisture is removed, and a second concentrated solution is obtained; the first time of ultracentrifugation is conducted on the second concentrated solution, and the supernate is taken andsubjected to the second time of ultracentrifugation, the supernate is removed, and precipitation is performed to obtain the exosome for stem cell secretion; normal saline is added for cleaning and centrifugation, the supernate is removed, and the exosome precipitate is obtained.

The invention provides an umbilical cord tissue cryopreservation and resuscitation method. The method comprises the following steps: S1, cutting umbilical cord tissues to obtain first tissue strips; S2, immersing the first tissue strips in a vitrification solution, and then directly cryopreserving the first tissue strips to obtain second tissue strips; and S3, resuscitating the second tissue strips to obtain third tissue strips, wherein the vitrification solution includes a first vitrification solution, a second vitrification solution and a third vitrification solution, and the step S2 includes the following processes: sequentially immersing the first tissue strips in the first vitrification solution, the second vitrification solution and the third vitrification solution, transferring thefirst tissue strips into liquid nitrogen, and cryopreserving the first tissue strips to obtain the second tissue strips. The umbilical cord strips are cryopreserved and resuscitated through a vitrification technology, so the operation time is shortened, the cryopreservation efficiency is improved, and the necrosis rate of the umbilical cord tissues in the cryopreservation and resuscitation processis reduced.

The invention relates to a method of inducing and differentiating human umbilical cord derived mesenchymal stem cells into cartilage cells. The method includes: in order to solve the problem that the prior art is low in differentiation efficiency, cleaning umbilical cord tissue to remove blood stain, cutting the same into small sections, dissecting the small sections to remove vascular tissue, cutting the small sections into pieces, and digesting to obtain a single mesenchymal stem cell; culturing the obtained mesenchymal stem cell in an amplification manner to the seventh generation to obtain a unicellular suspension, inoculating the unicellular suspension into a serum-free culture medium containing a cartilage differentiation inducer to continue culturing, replacing a fresh culture medium every other 3.5 days, and inducing for 14 days to obtain the cartilage cells. The method can efficiently differentiate the umbilical cord mesenchymal stem cells into the cartilage cells and is of important significance in the aspects of restoring cartilage tissue in human bodies and treating bone injury.

The invention discloses a canine mesenchymal stem cell bank and a construction method thereof. The construction method comprises the following steps: 1, collecting and detecting placentas and umbilical cords; 2, carrying out enzyme digestion on placenta and umbilical cord tissues; 3, collecting cells by using a specially-designed cell filter with multi-mesh sieves; 4, digesting and filtering the cells multiple times, and collecting cells with the particle size of about 10-25 [mu]m; 5, culturing the cells, and identifying the cells; and 6, carrying out liquid nitrogen refrigeration detection, preserving qualified mesenchymal stem cells, and establishing cell information archive to construct the canine placenta and umbilical cord mesenchymal stem cell bank. The mesenchymal stem cells obtained through the method have high activity, can be preserved for a long term, and are simple to operate. The mesenchymal stem cell bank is applied to the treatment of relevant diseases of species relationship similar canoidea.

We have disclosed an induced pluripotent stem cell and the method of preparing the induced pluripotent stem cell from a human umbilical cord tissue-derived cell. More particularly, we have disclosed a human umbilical cord tissue-derived iPS cell which may be differentiated into cells of ectoderm, mesoderm, and endoderm lineages.

The invention discloses a preparing method for clinic level cells for enhancing the immune modulating function of MSCs. The preparing method is suitable for culturing the mesenchymal stem cells from bone marrow, fat and the umbilical cord. A serum-free complete medium is adopted to culture the mesenchymal stem cells from umbilical cord tissue, a traditional method is improved by applying a secondary inoculation method, and the obtaining rate of primary cells is increased. Imidazoquinoline R848 with the concentration of 1-5 micrograms/milliliters and recombinant human interferon I FN-alpha-2b with the concentration of 100-200 units/milliliters are applied as pretreatment factors and obviously induce high expression of the MSCs and secretory cell factors VEGF, HGF and PGE-2, the capacity for modulating immune and promoting tissue regeneration of the MSCs is brought into play better, the multiplication capacity and the capacity for resisting NK cell killing of the MSCs can be improved obviously, and the pretreated MSCs have the enhanced capacity for suppressing lymphocyte proliferation and can be applied to treatment on the GVHD with T cells as the principal and other autoimmune diseases better.